Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022

BUY
$0.59 - $1.7 $30,432 - $87,686
51,580 New
51,580 $61,000
Q2 2020

Aug 13, 2020

SELL
$0.77 - $1.13 $13,617 - $19,984
-17,685 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$0.69 - $1.52 $172 - $380
250 Added 1.43%
17,685 $14,000
Q4 2019

Feb 12, 2020

SELL
$0.88 - $1.29 $6,871 - $10,073
-7,809 Reduced 30.93%
17,435 $17,000
Q3 2019

Nov 13, 2019

SELL
$1.03 - $1.75 $7,132 - $12,118
-6,925 Reduced 21.53%
25,244 $26,000
Q2 2019

Aug 07, 2019

SELL
$1.43 - $1.87 $18,680 - $24,427
-13,063 Reduced 28.88%
32,169 $58,000
Q1 2019

May 08, 2019

BUY
$1.18 - $1.91 $18,771 - $30,384
15,908 Added 54.25%
45,232 $85,000
Q4 2018

Feb 12, 2019

SELL
$1.01 - $2.78 $10,302 - $28,355
-10,200 Reduced 25.81%
29,324 $35,000
Q3 2018

Nov 13, 2018

BUY
$1.72 - $2.71 $28,896 - $45,528
16,800 Added 73.93%
39,524 $107,000
Q2 2018

Aug 02, 2018

BUY
$1.72 - $2.26 $39,085 - $51,356
22,724 New
22,724 $43,000
Q3 2017

Nov 14, 2017

SELL
$0.94 - $1.35 $588,313 - $844,917
-625,865 Closed
0 $0
Q2 2017

Aug 14, 2017

BUY
N/A
625,865
625,865 $983,000

Others Institutions Holding INFI

About INFINITY PHARMACEUTICALS, INC.


  • Ticker INFI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 89,277,904
  • Description
  • Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...
More about INFI
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.